Results for: iRhythm Technologies

iRhythm Technologies (IRTC) is set to release its quarterly earnings report on Wednesday, October 30th. Analysts anticipate a loss per share of -$0.58, but investors are hoping for positive surprises and upbeat guidance. This article provides a comprehensive analysis of iRhythm Technologies’s past performance, analyst sentiment, peer comparisons, and key financial metrics, helping investors make informed decisions ahead of the earnings announcement.

iRhythm Technologies, Inc. has received FDA clearance for its Zio AT device, a mobile cardiac telemetry device, after design changes. The company expects a second clearance soon, which could help it narrow the competitive gap in the market. This positive news has boosted IRTC stock by over 20%.